An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan

Published:2020-04-17 Issue: Volume: Page:1-11
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Saeki Hidehisa¹,Ishii Kanako²,Joshi Avani³,Bensimon Arielle G.⁴,Yang Hongbo⁴,Kawaguchi Isao²

Affiliation:

1. Department of Dermatology, Nippon Medical School, Tokyo, Japan;

2. Market Access, AbbVie GK, Tokyo, Japan;

3. Dermatology Health Economics and Outcomes Research, AbbVie Inc, Mettawa, IL, USA;

4. Health Economics and Outcomes Research, Analysis Group, Inc, Boston, MA, USA

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2020.1744505

Reference40 articles.

1. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database

2. Pathogenesis and therapy of psoriasis

3. Psychologic Factors in Psoriasis: Consequences, Mechanisms, and Interventions

4. Psoriasis causes as much disability as other major medical diseases

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of biologic sequential treatments for moderate-to-severe psoriasis: A Malaysian healthcare system perspective;PLOS ONE;2024-09-06

2. Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia;Cost Effectiveness and Resource Allocation;2023-12-09

3. Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysis;JAAD International;2021-12

4. Out‐of‐pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross‐sectional, non‐comparative, multicentre study;Journal of the European Academy of Dermatology and Venereology;2020-12-08

5. Risankizumab: A Review in Moderate to Severe Plaque Psoriasis;Drugs;2020-07-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3